Annexon, Inc. (NASDAQ:ANNX - Get Free Report) was the target of some unusual options trading on Thursday. Stock traders acquired 8,314 put options on the stock. This represents an increase of approximately 4,762% compared to the typical volume of 171 put options.
Analysts Set New Price Targets
ANNX has been the subject of several research analyst reports. Needham & Company LLC cut their price target on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright cut their price target on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.
Check Out Our Latest Report on ANNX
Annexon Price Performance
Shares of Annexon stock traded up $0.03 on Thursday, reaching $2.80. The company had a trading volume of 7,987,256 shares, compared to its average volume of 1,486,789. The firm has a market cap of $307.19 million, a price-to-earnings ratio of -2.37 and a beta of 1.30. The firm's 50-day moving average price is $2.27 and its two-hundred day moving average price is $2.78. Annexon has a 1 year low of $1.29 and a 1 year high of $7.85.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). As a group, analysts anticipate that Annexon will post -0.96 EPS for the current year.
Hedge Funds Weigh In On Annexon
Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in Annexon during the 4th quarter valued at $59,000. Legal & General Group Plc boosted its holdings in Annexon by 516.7% during the 4th quarter. Legal & General Group Plc now owns 85,535 shares of the company's stock valued at $439,000 after acquiring an additional 71,665 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Annexon during the 4th quarter valued at $252,000. Nuveen Asset Management LLC boosted its holdings in Annexon by 6.5% during the 4th quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company's stock valued at $13,956,000 after acquiring an additional 164,915 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in Annexon during the 4th quarter valued at $177,000.
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
